• In late July 2026, Myriad Genetics reported second-quarter results showing revenue of US$190.7 million versus US$213.1 million a year earlier, alongside a reduced full-year 2026 revenue outlook of US$770 million to US$790 million due to weaker Prenatal Health test volumes and more cautious assumptions for revenue per test.
• Despite the revenue decline, the company’s net loss narrowed sharply to US$43.2 million from a very large loss a year ago, highlighting significant cost or non-operational improvements even as testing volumes and pricing remain under pressure.
• We’ll now examine how the lowered full-year revenue guidance and Prenatal Health volume weakness affect Myriad Genetics’ existing investment narrative.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

Myriad Genetics Investment Narrative Recap

To own Myriad Genetics today, you need to believe its oncology and precision medicine portfolio can offset pressure in Prenatal Health and Pharmacogenomics, while losses narrow over time. The latest guidance cut keeps the near term focus on whether management can stabilize Prenatal Health volumes and revenue per test, which now looks like the key catalyst and the biggest risk. The sharp share price drop amplifies these concerns but does not change the underlying question of test demand and reimbursement.

Against this backdrop, the new technology licensing agreement with Burning Rock Biotech on homologous recombination deficiency testing is particularly relevant. It underscores Myriad’s push to deepen its oncology footprint and diversify beyond mature hereditary cancer and mental health tests, which could matter more if Prenatal Health remains weak. For investors watching the story, oncology partnerships like this one now sit alongside payer decisions and test pricing as crucial swing factors.

Yet while oncology partnerships may help over time, the immediate pressure on Prenatal Health volumes and revenue per test is something investors should be aware of...

Myriad Genetics' narrative projects $996.1 million revenue and $188.4 million earnings by 2029.

Uncover how Myriad Genetics' forecasts yield a $6.25 fair value, a 119% upside to its current price.

Exploring Other Perspectives

The most cautious analysts were already assuming modest revenue growth of about 4.7% a year and no profits by 2029, so this guidance cut could push their already pessimistic view even further, especially if reimbursement pressure on key tests tightens more than they had built into those forecasts.

Explore 3 other fair value estimates on Myriad Genetics - why the stock might be worth just $4.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Myriad Genetics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Myriad Genetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Myriad Genetics' overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.